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Abstract
Recent studies indicate that human induced pluripotent stem cells (hiPSCs) contain genomic 
structural variations and point mutations in coding regions. However, these studies have focused 
on fibroblast-derived hiPSCs, and it is currently unknown whether the use of alternative somatic 
cell sources with varying reprogramming efficiencies would result in different levels of genetic 
alterations. Here we characterize the genomic integrity of eight hiPSC lines derived from five 
different non-fibroblast somatic cell types. We show that protein-coding mutations are a general 
feature of the hiPSC state and are independent of somatic cell source. Furthermore, we analyze a 
total of 17 point mutations found in hiPSCs and demonstrate that they do not generally facilitate 
the acquisition of pluripotency and thus are not likely to provide a selective advantage for 
reprogramming.
INTRODUCTION
The induction of pluripotency in human somatic cells by defined transcription factors 
represents a breakthrough in regenerative medicine1–5. The generation of patient-specific 
human induced pluripotent stem cells (hiPSCs) and their autologous cell derivatives would 
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help to overcome the problems of immune rejection and tissue availability. However, the 
applications of cell therapies in human patients are subject to very stringent safety 
requirements, and there is a general concern in the field about the safety of hiPSCs.
Successful generation of hiPSCs depends on the complete reprogramming of the somatic 
epigenome to a pluripotent state while the genome remains unchanged. Although initial 
reports demonstrated that human embryonic stem cells (hESCs) and hiPSCs were very 
similar, recent reports have uncovered striking genetic and epigenetic differences between 
these two pluripotent cell types6–11. It has been shown that hiPSCs display protein-coding 
mutations, large-scale genomic rearrangements, persistent epigenetic marks from the 
somatic cell type of origin and aberrant methylation patterns6, 9, 11. These findings indicated 
that hiPSCs contain genomic defects that could preclude their use in stem cell therapies. 
However, most of these studies focused on fibroblast-derived hiPSCs and a more 
comprehensive analysis is essential to determine whether there are specific somatic cell 
types that may reprogram into hiPSCs with fewer (or perhaps none) of these aberrations. 
Additionally, it is unclear whether the protein-coding mutations found in hiPSCs provide 
any functional advantage and thus, are selected for during the process of reprogramming.
In this work, we characterize at single nucleotide resolution the genomic integrity of eight 
hiPSC lines derived from five different non-fibroblast somatic cell types with varied 
reprogramming efficiencies. Moreover, we functionally characterize the role of 17 point 
mutations found in hiPSCs for their ability to increase reprogramming efficiency. We 
demonstrate that the majority of these mutations do not favor the reprogramming process 
and suggest that most of them originated randomly or were initially present in the somatic 
population of origin. Our observations of the genetic abnormalities of hiPSCs will contribute 
to a deeper understanding of the reprogramming process.
RESULTS
hiPSC lines from varied cell types contain protein-coding mutations
We previously sequenced the protein-coding regions of 22 fibroblast-derived hiPSC lines 
and discovered that the hiPSCs analyzed carried between 2 and 14 point mutations in 
protein-coding regions6. In this study, we sought to determine if low reprogramming 
efficiency (and therefore a potentially higher level of selection pressure which could allow 
the fixation of advantageous mutations) or cell type of origin (as fibroblasts could possess a 
higher somatic mutation rate than other cell types) could contribute to the overall 
reprogramming-associated mutational load. To this end, we performed targeted exome 
sequencing on eight non-fibroblast derived hiPSC lines and their five somatic cell types of 
origin using an in-solution hybridization capture method (Supplementary Table S1). Somatic 
mutations in each hiPSC line were identified via pairwise comparison with the matched 
somatic cell of origin and independently confirmed with capillary Sanger sequencing. We 
identified a total of 40 point mutations throughout all the hiPSC lines analyzed, leading to an 
average of 5 coding mutations per line (Table 1). As we identified ~89% of expected total 
single nucleotide polymorphisms at high sequencing depth in protein-coding regions, this 
led to a projection of 45 total mutations in protein-coding regions, or approximately 6 
coding mutations per cell line. The levels of mutational load from each individual somatic 
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cell type were statistically indistinguishable, and within the range previously observed for 
fibroblast-derived hiPSC lines6 (Table 1). These results indicate that hiPSC-associated 
mutations cannot be avoided by using younger or potentially more genetically protected 
somatic cell sources as progenitor cells. Moreover, we determined that reprogramming 
efficiency, which varies between 0.001–3% for these cell types, did not seem to have a 
measurable effect on the hiPSC mutational load. Thus, reprogramming-associated point 
mutations appear to be a general feature of hiPSCs.
We next investigated whether mutations in hiPSCs were either enriched or depleted in 
protein coding-regions. To this end, we examined additional non-coding regions captured in 
our sequencing analysis, and found a similar mutation rate per base pair analyzed for both 
coding and non-coding regions (Table 2). We also investigated whether point mutations in 
hiPSCs tended to occur in active/ubiquitous or silent/tissue-specific genes. Among a total of 
132 mutated genes (from this study and Gore et al) annotated in the TiGER Database 
(TIssue-specific Gene Expression and Regulation)12, 37% of these genes showed tissue-
specific expression, which is very similar to the overall level of tissue specificity observed in 
the genes annotated in the database (34%; p=0.4975), indicating that mutations are not 
preferentially occurring in silent genes. We additionally checked for any potential 
enrichment of mutations in active or inactive transcriptional regions of the genome13. We 
found that mutations were not significantly enriched in the active or inactive chromatin 
regions of fibroblasts (p-value=0.79), hESCs (p-value=0.29), or hiPSCs (p-value=0.07). 
Furthermore, only one gene (NTRK3) was found mutated in more than one independent 
hiPSC line and mutated genes did not cluster in a specific functional pathway (Gore et al6 
and results herein). These combined findings suggest that mutations in hiPSCs are spread 
throughout both transcriptionally active and silent regions of the genome.
hiPSC-point mutations do not favor the process of reprogramming
We previously showed that at least half of reprogramming-associated point mutations pre-
exist in starting somatic cell populations at low frequency6. This leads to a hypothesis that a 
sub-population of somatic cells carrying certain mutations could be primed for 
reprogramming, which would be consistent with the elite model for reprogramming14. To 
investigate the functional potential of these mutations during reprogramming we first 
assessed whether mutated alleles were expressed in the hiPSC lines. We isolated RNA from 
3 hiPSC lines, reverse-transcribed it into cDNA, and sequenced a total of 6 transcripts of 
randomly selected genes found mutated in these hiPSC lines. We detected heterozygous 
expression of both mutant and wild-type alleles in all cases (Fig. 1) indicating that mutated 
transcripts are expressed in hiPSCs.
We next sought to determine if reprogramming-associated mutations could contribute 
functionally in facilitating the acquisition of pluripotency during reprogramming. From a 
total of 164 different genes found mutated in hiPSC lines (Gore et al6 and this study), we 
assayed the function of 17 candidate genes and their mutated forms during reprogramming 
(Supplementary Table S2). These candidate genes were selected based on the likelihood of 
the mutation to change protein function, the mutation type (only nonsynonymous mutations 
were analyzed) and whether the gene was known to be related to the maintenance and/or 
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acquisition of pluripotency6 (Table 1; Supplementary Fig. S1; Supplementary Table S2). We 
also analyzed the expression of these 17 genes in BJ fibroblasts, human umbilical vein 
endothelial cells (HUVEC), hESC and hiPSC lines to ensure gene expression in at least one 
of the somatic cell types used in this work (Supplementary Fig. S2). Due to the difficulty in 
predicting the functional consequences of each specific mutation, we first performed “loss-
of-function” reprogramming experiments to mimic a possible diminished activity or protein 
instability of the mutated form. To this end, we designed a panel of lentiviruses encoding 
shRNAs against the selected genes (Supplementary Fig. S3a), and co-infected each 
separately with retroviruses expressing OCT4, SOX2, KLF4 and cMyc (OSKC) in BJ 
fibroblasts (Fig. 2a). Moreover, to determine whether these effects were cell-type specific 
we performed similar reprogramming experiments in HUVEC (Supplementary Fig. S4a). If 
a genetic mutation was selected for its ability to facilitate reprogramming due to a loss of 
protein function, it would be expected that down-regulation of the mutated gene would 
increase reprogramming efficiency. A decrease in reprogramming efficiency was detected 
after down-regulation of FAIM3, SAMD3, ZNF16, MARCKSL1, NRP1, TRAF6, GSG1 and 
HK1, whereas no significant changes were detected after down-regulation of all but one of 
the assayed genes, POLR1C (Fig. 2a, Supplementary Fig. 4a, Supplementary Fig. S4b). 
Interestingly, we observed that down-regulation of POLR1C in BJ fibroblasts, but not in 
HUVEC, resulted in an increased reprogramming efficiency. However, it is unclear if the 
specific reprogramming-associated mutation in POLR1C would result in the same 
phenotype. Overall, our data suggest that protein-coding point mutations generally do not 
prime rare cells for reprogramming through the loss-of-function mechanism.
Next, we performed “gain-of-function” reprogramming experiments to determine whether 
expression of the mutated form facilitated cell reprogramming. To this end, we designed a 
panel of retroviruses encoding both the wild type form and the corresponding mutated form 
found in hiPSCs of each specific gene (see specific mutations in Supplementary Table S2; 
Supplementary Fig. S3b), and co-expressed them with OSKC in BJ fibroblasts and HUVEC 
(Fig. 2b, Supplementary Fig. S4c). If a mutation were selected during reprogramming due to 
a gain-of-function, it would be expected that expression of the mutated form would increase 
the reprogramming efficiency. We observed that only the expression of HK1 slightly 
increased reprogramming efficiency (Fig. 2b and Supplementary Fig. S4c). Importantly, we 
did not observe significant differences in reprogramming efficiency between cells over-
expressing the mutated forms and cells over-expressing their respective wild-type forms 
(Fig. 2b), indicating that the presence of the mutated protein does not increase 
reprogramming efficiency.
We have previously shown that both the mutant allele and the wild-type allele are expressed 
in hiPSCs (Fig. 1). However, it is possible that a similar level of expression of the wild-type 
and mutant protein forms is necessary in order for the mutation to influence reprogramming 
efficiency in a gain-of-function manner. To clarify this, we performed a reprogramming 
experiment where OSKC were co-expressed together with a similar total amount of 
retrovirus encoding either only the wild type form or both the wild-type (wt) and mutant 
(mut) forms of a mutated gene in an equal ratio (1:1). Using this strategy, we were able to 
compare the reprogramming efficiency of cells over-expressing wild-type and mutated 
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protein (wt/mut) in equal amounts with that of cells over-expressing wild-type protein alone 
(wt/wt). Interestingly, we did not observe any difference in reprogramming efficiency 
between cells over-expressing the wt/wt and wt/mut proteins (Fig. 3a). Finally, we 
investigated whether silencing of retroviral transgenes during reprogramming could mask a 
gain-of-function effect of the mutated genes at a later stage of reprogramming. To this, we 
analyzed the reprogramming efficiency of cells infected with retroviruses expressing OSKC, 
the wild type or mutated forms of the genes evaluated in this study, and a red fluorescent 
protein (RFP) reporter gene to monitor transgene silencing. Reprogramming efficiency was 
evaluated based on the number of Tra-1-60+/RFP+ colonies present at day 14. These 
colonies represent putative bona-fide hiPSC colonies, as they express the stem cell marker 
Tra-1-60 but lack silencing of the exogenous transgenes. Thus, we only considered 
reprogramming events where transgene expression was still active. Importantly, we did not 
observe differences in reprogramming efficiency between cells over-expressing the mutated 
forms and cells over-expressing their respective wild-type forms (Fig. 3b). Furthermore, we 
also evaluated reprogramming efficiency in the same experiment at day 14 by analyzing the 
number of Tra-1-60+/RFP− colonies (evaluating putative bona-fide hiPSC colonies where 
transgene silencing occurred), and obtained a similar result (data not shown). Overall, these 
data suggest that most of these mutated genes do not facilitate reprogramming through a 
gain-of-function or loss-of-function mechanism.
DISCUSSION
Our work demonstrates that hiPSCs contain protein-coding mutations independent of the 
cell type of origin (as we analyzed hiPSC lines derived from five tissue types). Moreover, 
we determined that reprogramming efficiency, and therefore the level of selection pressure 
which could allow the fixation of advantageous mutations, did not to have a measurable 
effect on the hiPSC mutational load. Although the functional consequences of individual 
protein-coding mutations detected in hiPSCs remain to be characterized, these alterations 
could potentially contribute to the functional differences observed between hiPSC lines15–17. 
Two independent groups have recently reported the whole genome sequencing of human 
and murine iPSC lines and their corresponding somatic cell lines18–19. They identified 
hundreds of single nucleotide variants (SNVs) in non-coding regions as well as an average 
of 6–12 SNVs in coding regions18–19, which is consistent with our results6. Importantly, 
their data suggest that much of the genetic variation in iPSC clones pre-exists in the somatic 
population of origin and is fixed as a consequence of cloning individual cells during iPSC 
generation18–19. Although these reports supported previous observations6, they did not 
investigate whether identified mutations contribute functionally to facilitate the acquisition 
of pluripotency during reprogramming.
In this work, we show evidence suggesting that most reprogramming-associated point 
mutations do not provide a detectible selective advantage towards a reprogrammed state. 
Since inhibiting wild type POLR1C expression had a positive impact on reprogramming 
efficiency, we cannot rule out a potential role of the mutation found in POLR1C in 
facilitating reprogramming. If this is the case, the fact that down-regulation of POLR1C 
increases reprogramming efficiency in fibroblasts but not in HUVEC could indicate the 
existence of tissue-specific mutations affecting reprogramming efficiency, as PORL1CP278R 
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was found in one hiPSC line derived from human fibroblasts. Although it remains possible 
that untested mutated genes or a combination of mutations in a certain cellular context could 
play a role, the findings that only one gene (NTRK3) was found mutated in 2 out of 30 
independent hiPSC lines, that mutated genes do not cluster in a specific functional pathway 
that could explain their selection during the reprogramming process, and that non-coding 
regions showed a similar mutational load, indicate that reprogramming-associated mutations 
seem to occur through a random process without selection and/or be initially present in the 
somatic population of origin18–19. It has been suggested that genomic alterations (i.e. 
duplications, deletions and mutations) are selected for during reprogramming, yet this has 
not been demonstrated6–11. In contrast to well-established recurrent genomic aberrations 
(e.g. chromosome 12 duplications) present in hESC or hiPSC lines that are functionally 
selected upon prolonged culture8, our results suggest that reprogramming-associated point 
mutations generally do not affect reprogramming efficiency although there could be 
exceptions. To our knowledge, the data provided herein provides for the first time a 
functional analysis of the role of specific genomic alterations (i.e. point mutations in coding 
regions) on the reprogramming process and have potential implications for the future of the 
hiPSC field in regenerative medicine.
METHODS
Cell culture
The hiPSC lines ASThiPS4F4, ASThiPS4F5, HUVhiPS4F1, HUVhiPS4F3, FhiPS4F7, 
NSChiPS2F and FhiPS3F1 were already described6, 20–22, and obtained from existing 
cultures. The hiPSC lines MSChiPS4F4, MSChiPS4F8 and KhiPS4F8 show all the 
requirements (morphology, pluripotent gene expression, normal karyotype and in vivo 
differentiation by teratoma formation) to define them as hiPSC cell lines. Derived hiPSCs 
were cultured as described24. 293T cells and BJ human fibroblasts (ATCC, CRL-2522) were 
cultured in DMEM (Invitrogen) supplemented with 10% FBS and 0.1 mM non-essential 
aminoacids. HUVEC cells were obtained from Lonza (C-2519A) and grown with EGM-2 
media (Lonza) as recommended. MSCs were kindly provided by Cécile Volle (Sanofi-
Aventis) and grown in α-MEM (Invitrogen) containing 10% FBS (Hyclone), penicillin/
streptomycin, sodium pyruvate, nonessential amino acids, and L-glutamine (all from 
Invitrogen). Human keratinocytes were obtained and cultured as previously described23.
hiPSC generation
To generate hiPSCs (KhiPS4F8, MSChiPS4F4 and MSChiPS4) or to evaluate 
reprogramming efficiency, experiments were performed as described with minor 
modifications24. Briefly, BJ fibroblasts, keratinocytes, MSCs or HUVEC cells were infected 
with an equal ratio of retroviruses or retroviruses plus lentiviruses by spinfection of the cells 
at 1850 rpm for 1 hour at room temperature in the presence of polybrene (4 μg/ml). After 
one (in case of the HUVEC cells), two (in case of the BJs fibroblasts or keratinocytes) or 
three (in case of the MSCs) viral infections viral infections, cells were trypsinized and 
transferred onto fresh irradiated mouse embryonic or human fibroblasts (iMEFs or iHFs) 
where correspond. One day after, cells were switched to hES cell medium (DMEM/F12 or 
KO-DMEM (Invitrogen) supplemented with 20% Knockout Serum Replacement 
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(Invitrogen), 1 mM L-glutamine, 0.1 mM non-essential amino acids, 55 μM β-
mercaptoethanol and 10 ng/ml bFGF (Joint Protein Central)). Depending on the cell type of 
origin, colonies were stained for Nanog expression at day 18 (in the case of HUVEC-derived 
hiPS cells) or 24 (in the case of BJ fibroblasts-derived hiPS cells) or isolated to establish cell 
lines. To calculate the efficiency of reprogramming, we plated the same number of infected 
HUVEC or BJ fibroblasts cells on iMEFs after the infection and the relative percentage of 
Nanog+ colonies to the value of the number of colonies generated with HUVEC or BJ 
fibroblasts cells infected with pLVTHM lentiviruses or GFP-expressing retroviruses 
correspondingly is shown.
Plasmid construction
The reprogramming plasmids pMX-OCT4, pMX-SOX2, pMX-KLF4, pMX-cMyc together 
with pLVTHM were obtained from Addgene (plasmids 17217, 17218, 17219, 17220 and 
12247 respectively). For the construction of pMX-NTRK3, pMX-FAIM3, pMX-POLR1C, 
pMX-GDF3 and pMX-HK1 (fragment corresponding to the nucleotides 277-2753), specific 
coding region sequences were amplified by PCR from Human ORFeome library plasmids 
containing the corresponding cDNAs. cDNA fragments were digested with adequate 
restriction enzymes, purified and subcloned into linearized pMX plasmid. For the 
construction of pMX-CCKBR, pMX-SAMD3, pMX-UBA2, pMX-TRAF6, pMX-
MARCKSL1, pMX-CD1B, pMX-GSG1, pMX-NRP1, pMX-NEK11, pMX-CTSL1, pMX-
ASB3 and pMX-ZNF16, specific pDONR223 plasmids from Human ORFeome library 
containing the corresponding cDNAs were used to transfer the cDNAs to the vector pMX-
GW (Addgene, 18656). The transfer was achieved by using the Gateway LR Clonase 
enzyme mix (Invitrogen). The plasmids pMX-p16, pMX-CDK4, pMX-CycD1, pLVTHM-
CycE and pLVTHM-p53 were generated as described24, 25. The plasmid pMX-RFP was 
kindly provided by Dr. Guanghui Liu (Gene Expression Laboratory, The SALK Insitute, La 
Jolla, CA). For the introduction of specific point mutations in the coding sequences of the 
above genes (see Supplementary Table S2 for specific mutations) the QuickChange Site-
Directed Mutagenesis kit was used (Stratagene; see Supplementary Table S3 for specific 
primers). For the generation of plasmids encoding shRNAs against the genes used in this 
study, specific oligos (see Supplementary Table S3 for specific primers) were annealed, 
phosphorylated with T4 kinase and ligated into MluI/ClaI-linearized pLTVHM plasmid. The 
design of 3 different pairs of shRNAs was carried out using the SFold software (http://
sfold.wadsworth.org/) and knockdown efficiency was assayed in 293T cells. The most 
efficient pairs of shRNAs were assayed in HUVEC or BJ fibroblasts cell (Supplementary 
Fig. S1a) and used in the corresponding experiments. All constructs generated were 
subjected to direct sequencing to rule out the presence of mutations.
Retroviral and lentiviral production
Moloney-based retroviral vectors (pMX and derived) and second generation lentiviral 
vectors (pLVTHM and derived) were co-transfected with packaging plasmids to generate 
viral particles in 293T cells using Lipofectamine (Invitrogen) as previously described24.
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Imnunofluorescence analysis for the detection of pluripotent markers in hiPSCs or for the 
detection of differentiation-associated markers in teratomas were performed as described22. 
Immunohistochemical/immunoflorescence detection of Nanog or Tra-1-60 was performed 
as described24.
RNA isolation and real time-PCR analysis
Total RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacturer’s 
recommendations. cDNA was synthesized using the SuperScript II Reverse Transcriptase kit 
for RT-PCR (Invitrogen) or the RT Supermix M-MuLV kit (BioPioneer). Real-time PCR 
was performed using the SYBR-Green PCR Master mix (Applied Biosystems) in the ViiA 7 
Real Time PCR System (Applied Biosystems). GAPDH expression was used to normalize 
values of gene expression and data is shown as fold change relative to the value of the 
sample control. All the samples were done in triplicate. Primers used for real time-PCR 
experiments are listed in Supplementary Table S3.
Whole genome library construction
Library construction was performed as previously described6, 26. Briefly, for each sample, 
roughly 1.5 to 3 μg of genomic DNA (in 100 μl volumes) was sheared with a Covaris AFA. 
The fragmented genomic DNA was end repaired, A-tailed, and ligated to sequencing 
adaptors, with a purification step between each process. The purified ligated products were 
then amplified by PCR to generate whole-genome libraries.
In-Solution Hybridization capture with DNA baits
Liquid exome capture was performed as previously described6.
Consensus sequence generation and variant calling
Variant calling was performed as previously described6. Briefly, reads obtained from the 
Illumina Genome Analyzer were post-processed and quality filtered using GERALD, 
mapped to the genome using BWA, downsampled using Picard, and used to generate a 
consensus sequence for each sample using GATK. The consensus sequences were then 
compared to find candidate novel mutations in hiPSCs6. Sites where each hiPSC line 
showed heterozygous SNPs not observed in the progenitor line were considered as candidate 
mutations if no allelic content was present in the somatic progenitor and if the candidate 
mutation had not previously been observed in other samples or the dbSNP database.
Sanger validation of candidate mutations
Genomic DNA of both the hiPSC line and its somatic progenitor (6 ng each) was amplified 
in separate 50 μl PCR reactions with 100 nM of specifically designed forward and reverse 
primers around the mutation site (primers available under request) and 25 μl of Taq 2x 
master mix (NEB) at 94 °C for 2 minutes, followed by 35 cycles of 94 °C for 30 seconds; 57 
°C for 30 seconds; and 72 °C for 30 seconds, and final extension at 72 °C for 3 minutes. The 
PCR products were then purified with Qiagen Qiaquick columns, and 10 ng of purified 
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DNA was pre-mixed with 25 pmol of the forward primer for Sanger sequencing at Genewiz 
Inc.
Statistical Analysis/TiGER Database
To check for enrichment of reprogramming-associated mutations in genes that are expressed 
in a tissue-specific manner, the fraction of UniGene IDs corresponding to mutated genes 
called as “tissue-specific” in the TiGER database was identified as 49/132 (37%). As 
6,699/19,526 (34%) of the genes annotated in the TiGER database are considered to be 
tissue-specific, a χ2 test with one degree of freedom can be used to test for equivalency of 
distribution. The obtained χ2 value is 0.460, indicating that the fraction of mutated hiPSC 
genes that are tissue-specific is not significantly different than that found in a random 
sample of genes (P-value = 0.4975). Reprogramming-associated mutations therefore do not 
appear to be enriched in tissue-specific genes.
Statistical Analysis/Active and Inactive Chromatin States
To check for enrichment of reprogramming-associated mutations in active or inactive 
chromatin, we utilized a χ2 test with three degrees of freedom to test for equivalency of 
distribution. We identified the chromatin state of each mutated gene using previously 
published data13. This data divided each gene into one of four categories: no trimethylation, 
H3K4 Trimethylation, H3K27 Trimethylation, or both. We compared the distribution of 
mutated genes across each of these four categories with the expected distribution for all 
genes in three cell types: Fibroblasts, ESCs, and iPSCs13. The obtained χ2 values were 1.03 
(p-value=0.79), 3.78 (p-value=0.29), and 6.97 (p-value=0.07), respectively, indicating that 
the distribution of mutated hiPSC genes in each chromatin region is not significantly 
different than expected by random chance (alpha=0.01). Reprogramming-associated 
mutations therefore do not appear to be enriched in active or inactive chromatin states.
Non-coding versus Coding mutations
To compare the mutation rates per base pair in coding and non-coding regions of the 
genome, variant calling was performed as above on non-coding regions of the genome 
surviving library enrichment in eight hiPSC lines and their progenitor lines. The mutation 
rate per base pair was then estimated by dividing the number of candidate coding and non-
coding mutations by the number of exomic and non-coding base pairs covered. The average 
coding and non-coding mutation rates were compared.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutated alleles are expressed in hiPSC lines
Sanger chromatograms showing the results of RNA Sequencing analysis performed on the 
indicated genes found mutated in the indicated hiPSC lines. Dashed lines highlight the 
point-mutated nucleotide. Note the expression of both reference and mutated alleles in all 
cases analyzed.
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Figure 2. Evaluation of the functional effect of hiPSC mutations on reprogramming efficiency
(a, b) Human BJ fibroblasts were infected with retroviruses encoding OSKC, and either 
lentiviruses encoding shRNAs against the indicated proteins (a) or retroviruses encoding the 
wild type or mutated proteins (b). Relative reprogramming efficiencies (evaluated as 
percentage of Nanog+ colonies) are shown as fold change normalized to the averaged 
efficiency observed in pLVTHM (a) or pMX-GFP (b) infected fibroblasts. In (a) 
lentiviruses encoding shRNAs against CycE1 or p53 were used as controls of reduced or 
increased reprogramming efficiency, respectively. In (b) retroviruses encoding p16 or the 
pair CDK4/CycD1 were used as controls of reduced or increased reprogramming efficiency, 
respectively. For (a), 20,000 infected cells were plated when shRNAs against POLR1C and 
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p53 were used and 70,000 infected cells were plated under all other conditions. For (b), a 
total of 25,000 infected cells were plated under all conditions. Two independent experiments 
with two biological replicates were carried out. All error bars depict the standard deviation.
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Figure 3. Retroviral silencing or wild-type/mutant gene ratio do not alter reprogramming 
efficiency
(a) HUVEC cells were infected with retroviruses encoding OSKC, and a similar total 
amount of retroviruses encoding only the wild type form or both, the wild-type (wt) and 
mutant (mut) forms of the protein in an equal proportion. (b) HUVEC cells were infected 
with retroviruses encoding OSKC, red fluorescence protein (RFP) and the wild type or 
mutated forms of the genes indicated. Relative reprogramming efficiencies (evaluated as 
percentage of Tra-1-60+ colonies) are shown as fold change normalized to the averaged 
efficiency observed in GFP-infected HUVECs. 10,000 infected cells were plated under all 
the conditions. Two independent experiments with two biological replicates were carried 
out. All error bars depict the standard deviation.
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